// App-Quantinova.ai

P1486 : TRIALS IN PROGRESS: THE THRIVE STUDIES EVALUATING THE EFFICACY, SAFETY, AND LONG-TERM TREATMENT WITH INCLACUMAB, A P-SELECTIN INHIBITOR, IN PATIENTS WITH SICKLE CELL DISEASE

Researchers

Presenter

  • Biree Andemariam

Principal Investigators

  • Adlette Inati

  • Caterina Minniti

  • Clark Brown

  • Margot Hottmann

  • Sarah Gray

  • Carolyn Hoppe

  • Mark Davis

  • Patrick Yue

Medical Centers

  • New England Sickle Cell Institute at the University of Connecticut, Farmington, CT

  • Albert Einstein College of Medicine,Bronx,Verenigde Staten

  • Albert Einstein College of Medicine, Bronx, New York, United States

  • Lebanese American University, Byblos and Beirut, Nini Hospital,Tripoli,Líbano

  • Global Blood Therapeutics, South San Francisco, CA

  • Clinic of Pediatric Hematology Oncology, Department of Woman's and Child's Health, Azienda Ospedale – Università di Padova,Padua,Italie

  • New England Sickle Cell Inst

  • Alb

  • New England Sickle Cell Institute at the University of Connecticut, Farmington, CT

  • Global Blood Therapeutics,South San Francisco,Verenigde Staten

  • Clinic of Pediatric Hematology Oncology, Department of Woman's and Child's Health, Azienda Ospedale – Università di Padova,Padua,Italie

  • Albert Einstein College of Medicine,Bronx,Verenigde Staten

  • Aflac Cancer & Blood Disorders Center of Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA

  • Albert Einstein College of Medicine, Great Neck, NY

  • Lebanese American University, Beirut and Nini Hospital, Tripoli, Lebanon

  • New England Sickle Cell Institute, University of Connecticut Health,Farmington,États-unis

  • Lebanese American University, Byblos and Beirut, Nini Hospital,Tripoli,Líbano

  • Global Blood Therapeutics, South San Francisco, CA

  • Lebanese

  • New England Sickle Cell Institute, University of Connecticut Health,Farmington,États-unis

  • Albert Einstein College of Medicine,Bronx,États-unis

  • Global Blood Therapeutics,South San

  • Aflac Cancer and Blood Disorder Center of Children's Healthcare of Atlanta and Department of P

  • Global Blood Therapeutics,South San Francisco,Verenigde Staten

  • Lebanese American University, Beirut and Nini Hospital, Tripoli, Lebanon

  • Global Blood Therapeutics, South San Francisco, CA, United States.

  • Clinic of Pediatric Hematology Oncology, Department of Woman's and Child's Health, Azienda Ospedale – Università di Padova,Padua,Italie

  • Lebanese American University, Byblos and Beirut, Nini Hospital,Tripoli,Líbano

  • Albert Einstein College of Medicine,Bronx,États-unis

  • Global Blood Therapeutics,South San Francisco,Estados Unidos

  • Aflac Cancer & Blood Disorders Center of Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA

Locations

  • United States

  • United Kingdom

  • Lebanon

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Sickle cell anemia

Biomarkers

  • Volatile organic compounds

Drug/Treatment

  • Inclacumab

  • Hydroxyzine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT04935879

  • NCT04927247

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved